Category Archives: News
Prevalence and Predictors of Young-Onset Colorectal Neoplasia: Insights from a Nationally Representative Colonoscopy Registry
A disturbing increase in early-onset colorectal cancer (EOCRC) has prompted recent guidelines to recommend lowering the CRC screening starting age from 50 to 45 years old for average risk individuals. Little is known about the prevalence of colorectal … Continue reading
How do we predict a patient’s disease course and whether they will respond to specific treatments?
Gastroenterologists will be all too familiar with the difficult decisions that managing IBD often presents. How aggressively should I treat this patient? Do I expect them to have a mild or aggressive form of disease? Do they need a biologic? If so, whi… Continue reading
Is prevention the best way to modify inflammatory bowel disease? How close are we?
Breaking through the therapeutic ceiling: what will it take?
Outcomes for patients starting a new treatment for inflammatory bowel disease (IBD) are characterised by uncertainty of treatment response. Although it is natural to hope that new treatments will be characterised by better efficacy, remission is still … Continue reading
Point-of-care testing and home testing: pragmatic considerations for widespread incorporation: stool tests, serum tests, intestinal ultrasound
Breaking through the biologic therapy efficacy plateau for inflammatory bowel disease requires the strategic development of personalized biomarkers in the tight control model. After risk stratification early in the disease course, targeted serial monit… Continue reading
How should pain, fatigue and emotional wellness be incorporated into treatment goals for optimal management of IBD?
Early diagnosis and the optimal control of inflammation, with a continuous cycle of assessment, treatment, monitoring and adjustment of therapy is best practice for the management of IBD. However, patients express frustration with ongoing challenging s… Continue reading
Artificial Intelligence for Disease Assessment in IBD: How Will it Change Our Practice?
Artificial intelligence (AI) has arrived and it will directly impact how we assess, monitor, and manage inflammatory bowel diseases (IBD). Advances in the machine learning methodologies that power AI have produced astounding results for replicating exp… Continue reading
Evolving short- and long-term goals of management of IBD: getting it right, making it last
Short- and long-term treatment targets in inflammatory bowel diseases (IBD) evolved during the last decade, shifting from symptom control to endoscopic healing and patient-centered parameters. STRIDE-II consensus placed these targets on a timeline from… Continue reading
Time to revisit disease classification in IBD: is the current classification of IBD good enough for optimal clinical management?
Inflammatory bowel disease (IBD), historically subdivided into Crohn’s disease and ulcerative colitis, is a very heterogeneous condition. While the tendency in medicine is to try and reduce complexity, IBD is a disease that cannot justify a one-size-fi… Continue reading
The future of precision medicine to predict outcomes and control tissue remodeling in inflammatory bowel disease
Inflammatory bowel disease is characterised by significant interindividual heterogeneity. With a wider selection of pharmacological and non-pharmacological interventions available and in advanced developmental stages, a priority for the coming decade i… Continue reading